Loading clinical trials...
Loading clinical trials...
To study the effectiveness and safety of adding Rosiglitazone, an insulin sensitizing agent to people with chronic hepatitis C infection genotype 1 with fatty liver disease, who are being treated with...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Beth Israel Medical Center
NCT05330923 · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and more
NCT03481829 · Diabetes Mellitus, Obesity, and more
NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more
NCT07265544 · Liver Neoplasm, HBV Infection, and more
NCT07403604 · Hyperinsulinemia, Insulin Resistance, and more
Beth Israel Medical Center - Philipps Ambulatory Care Center
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions